Case Fatalities in Hospitalised COVID-19 Patients in the UK
Case Fatalities in Hospitalised COVID-19 Patients in the UK: An ISARIC Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Edinburgh, United Kingdom
- University of Edinburgh
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients admitted with a proven or high likelihood of COVID-19
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Hospitalisations
All hospitalised COVID patients
|
Characteristics of the patients
Specific treatments used on COVID-19 patients
Triage criteria for treating COVID-19 patients
Capacity of hospitals
|
|
Critical care
All hospitalised COVID patients in critical care
|
Characteristics of the patients
Specific treatments used on COVID-19 patients
Triage criteria for treating COVID-19 patients
Capacity of hospitals
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Case fatality
Time Frame: 23 weeks
|
The proportion of new admissions with COVID-19 who died over time
|
23 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Annemarie B Docherty, Usher Institute, University of Edinburgh
- Principal Investigator: Ewen M Harrison, Usher Institute, University of Edinburgh
- Principal Investigator: Rachel H Mulholland, Usher Institute, University of Edinburgh
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ISARIC_COVID_CF
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
NCT04981769Not yet recruiting
-
NCT04885764Recruiting
-
NCT04608305Completed
-
NCT04864925Completed
-
NCT05045846Completed
-
NCT04973735Active, not recruiting
-
NCT04773756Completed
Clinical Trials on Patient Characteristics
-
NCT07143240CompletedAdult Patients Developing Optic or Peripheral Neuropathy | While Receiving Tedizolid Therapy Between July 2019 and December 2024
-
NCT07222891Not yet recruitingWellbeing | Olfactory Dysfunction
-
NCT06899906RecruitingEfficacy and Safety of Dalbavancin | In Subjects Who Received SAT with DAL | For Acute or Chronic Infections Between July 2019 and December 2024
-
NCT07429968Not yet recruitingDSPPea34 | Young People Aged 6-18 | Acute and Mild Psychological Disorders
-
NCT05350930CompletedChemotherapy Effect | G-CHOP Chemotherapy | R-CHOP Chemotherapy
-
NCT06744920Recruiting
-
NCT04547634CompletedCancer | Survivorship | Cancer Metastatic
-
NCT05978128RecruitingBreast Carcinoma | Lung Carcinoma
-
NCT05515198CompletedUrinary Incontinence